{"authors": [["Fayand", "A", "A", "Department de m\u00e9decine interne, DHUI2B, d\u00e9partement hospitalo-universitaire inflammation, immunopathologie, bioth\u00e9rapie, h\u00f4pital Tenon, universit\u00e9 Paris 6, Pierre et Marie Curie, Assistance publique-h\u00f4pitaux de Paris (AP-HP), 4 rue de la Chine, 75020 Paris, France; Centre de r\u00e9f\u00e9rence des maladies auto-inflammatoires rares et de l'amylose inflammatoire (CEREMAIA), CHU de Tenon, 75020 Paris, France."], ["Sarrabay", "G", "G", "Laboratoire de g\u00e9n\u00e9tique, CHU de Montpellier, 34090 Montpellier, France; Centre de r\u00e9f\u00e9rence des maladies auto-inflammatoires rares et de l'amylose inflammatoire (CEREMAIA), CHU de Tenon, 75020 Paris, France."], ["Belot", "A", "A", "Inserm U1111, service de rhumatologie p\u00e9diatrique, h\u00f4pital Femme-M\u00e8re-Enfant, universit\u00e9 Lyon 1, 69677 Bron, France; Centre de r\u00e9f\u00e9rence des rhumatismes et auto-immunit\u00e9 syst\u00e9mique de l'enfant (RAISE), 75015 Paris, France."], ["Hentgen", "V", "V", "Service de p\u00e9diatrie g\u00e9n\u00e9rale, centre hospitalier de Versailles, 78150 Versailles, France; Centre de r\u00e9f\u00e9rence des maladies auto-inflammatoires rares et de l'amylose inflammatoire (CEREMAIA), CHU de Tenon, 75020 Paris, France."], ["Kone-Paut", "I", "I", "Service de rhumatologie p\u00e9diatrique, CHU de Bic\u00eatre, universit\u00e9 de Paris Sud, AP-HP, 94270 Kremlin-Bic\u00eatre, France; Centre de r\u00e9f\u00e9rence des maladies auto-inflammatoires rares et de l'amylose inflammatoire (CEREMAIA), CHU de Tenon, 75020 Paris, France."], ["Grateau", "G", "G", "Department de m\u00e9decine interne, DHUI2B, d\u00e9partement hospitalo-universitaire inflammation, immunopathologie, bioth\u00e9rapie, h\u00f4pital Tenon, universit\u00e9 Paris 6, Pierre et Marie Curie, Assistance publique-h\u00f4pitaux de Paris (AP-HP), 4 rue de la Chine, 75020 Paris, France; Centre de r\u00e9f\u00e9rence des maladies auto-inflammatoires rares et de l'amylose inflammatoire (CEREMAIA), CHU de Tenon, 75020 Paris, France."], ["Melki", "I", "I", "Service de p\u00e9diatrie g\u00e9n\u00e9rale, maladies infectieuses et m\u00e9decine interne p\u00e9diatrique, centre hospitalier Robert-Debr\u00e9, 75019 Paris, France; Centre de r\u00e9f\u00e9rence des rhumatismes et auto-immunit\u00e9 syst\u00e9mique de l'enfant (RAISE), 75015 Paris, France."], ["Georgin-Lavialle", "S", "S", "Department de m\u00e9decine interne, DHUI2B, d\u00e9partement hospitalo-universitaire inflammation, immunopathologie, bioth\u00e9rapie, h\u00f4pital Tenon, universit\u00e9 Paris 6, Pierre et Marie Curie, Assistance publique-h\u00f4pitaux de Paris (AP-HP), 4 rue de la Chine, 75020 Paris, France; Centre de r\u00e9f\u00e9rence des maladies auto-inflammatoires rares et de l'amylose inflammatoire (CEREMAIA), CHU de Tenon, 75020 Paris, France. Electronic address: s.georgin.lavialle@gmail.com."]], "date": "2017-12-19", "id": "29273180", "text": "Deficiency of adenosine deaminase 2 (DADA2) is a recently described auto-inflammatory disorder. It is an autosomal recessive inherited disease, caused by mutations in the ADA2 gene (formerly known as CECR1) encoding ADA2 enzyme. Besides its role in the purine metabolism, it has been postulated that ADA2 may act as a growth factor for endothelial cells and in the differenciation of monocytes. Thus, deficiency of ADA2 would lead to endothelial damage and a skewing of monocytes into M1 pro-inflammatory macrophage, causing DADA2 manifestations. Three core clinical features have been described: inflammatory-vascular signs, hematologic abnormalities and immunodeficiency. Clinically, patients display intermittent fever, cutaneous vascular manifestations, such as livedo, ischemic strokes, arthralgia and abdominal pain crisis. Corticosteroids and immunosuppressive agents (i.e. cyclophosphamide, azathioprine, ciclosporin, methotrexate) appear to be poorly effective. Although the mechanism has not been elucidated, anti-TNF agents have been proven efficient in DADA2 and should therefore be used as first line therapy for vasculitis. Role of anti-platelet and anticoagulant therapies in stroke-prophylaxis remains to be discussed, as those patients display a high risk of intracranial bleeding.", "doi": "10.1016/j.revmed.2017.11.006", "title": "[Multiple facets of ADA2 deficiency: Vasculitis, auto-inflammatory disease and immunodeficiency: A literature review of 135 cases from literature].", "journal": ["La Revue de medecine interne", "Rev Med Interne"]}